Jordana E Hoppe
Overview
Explore the profile of Jordana E Hoppe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoppe J, Kasi A, Pittman J, Jensen R, Thia L, Robinson P, et al.
Lancet Respir Med
. 2025 Jan;
13(3):244-255.
PMID: 39756425
Background: In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor-tezacaftor-deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance...
2.
Metcalf A, Martiniano S, Sagel S, Zaretsky M, Zemanick E, Hoppe J
J Cyst Fibros
. 2024 Dec;
PMID: 39645477
As cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies including elexacaftor/tezacaftor/ivacaftor (ETI) have become widely used in eligible patients with cystic fibrosis (CF), the use of these medications in pregnant...
3.
Mayer-Hamblett N, Gifford A, Kloster M, Russell R, Braun A, Gibson R, et al.
Ann Am Thorac Soc
. 2024 Jul;
21(11):1507-1515.
PMID: 39041864
Evaluating approaches to reduce treatment burden is a research priority among people with cystic fibrosis on highly effective modulators, including elexacaftor-tezacaftor-ivacaftor (ETI). We sought to evaluate the impact of discontinuing...
4.
Good A, Shannon J, Brinton J, Hoppe J
Pediatr Pulmonol
. 2024 May;
59(10):2597-2605.
PMID: 38780201
Introduction: Limited data exist on the gross motor abilities of children with cystic fibrosis (CF). The objective of this research project was to implement a systematic gross motor assessment in...
5.
Hoppe J, Sjoberg J, Hong G, Poch K, Zemanick E, Thee S, et al.
J Cyst Fibros
. 2024 Mar;
23(4):725-733.
PMID: 38429150
The COVID-19 pandemic necessitated a rapid shift in clinical research to perform virtual visits and remote endpoint assessments, providing a key opportunity to optimize the use of remote endpoints for...
6.
Sanders D, Bartz T, Zemanick E, Hoppe J, Stukovsky K, Cogen J, et al.
Ann Am Thorac Soc
. 2023 Sep;
20(12):1769-1776.
PMID: 37683122
Despite the high prevalence and clear morbidity of cystic fibrosis (CF) pulmonary exacerbations (PEx), there have been no published clinical trials of outpatient exacerbation management. To assess the feasibility of...
7.
Goralski J, Hoppe J, Mall M, McColley S, McKone E, Ramsey B, et al.
Am J Respir Crit Care Med
. 2023 Mar;
208(1):59-67.
PMID: 36921081
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and effective in people with cystic fibrosis (CF) aged ⩾6 years with at least one allele but has not been studied in...
8.
Jordan K, Zemanick E, Taylor-Cousar J, Hoppe J
Expert Rev Respir Med
. 2023 Feb;
17(2):97-108.
PMID: 36803356
Introduction: Cystic fibrosis is a life-limiting, autosomal recessive genetic disorder resulting in multi-organ disease due to CF transmembrane conductance regulator () protein dysfunction. CF treatment previously focused on mitigation of...
9.
Wolfe A, Gilley S, Waldrop S, Olson C, Harding E, Widmer K, et al.
Front Pediatr
. 2023 Jan;
10:1083155.
PMID: 36683818
Background: Universal newborn screening changed the way medical providers think about the presentation of cystic fibrosis (CF). Before implementation of universal screening, it was common for children with CF to...
10.
Sagel S, Kupfer O, Wagner B, Davis S, Dell S, Ferkol T, et al.
Ann Am Thorac Soc
. 2022 Aug;
20(1):67-74.
PMID: 35984413
The role of airway inflammation in disease pathogenesis in children with primary ciliary dyskinesia (PCD) is poorly understood. We investigated relationships between sputum inflammation measurements, age, lung function, bronchiectasis, airway...